Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Linda Stein Gold, MD

Implementing Remission Goals in Psoriasis Practice

In the final episode, ‘Implementing Remission Goals in Psoriasis Practice,’ the panelists focus on the practical application of remission-focused strategies in psoriasis management, emphasizing how clinicians can translate evolving treatment goals into everyday practice. The expert faculty highlight that while formal definitions of on-treatment remission provide valuable guidance, implementation does not require rigid protocols. Instead, simply recognizing remission as an achievable goal can shift the clinical mindset and elevate standards of care in psoriasis.

They discuss the importance of setting clear expectations with patients, particularly the goal of achieving and maintaining complete skin clearance. The faculty emphasize that patients typically seek the most effective therapy available and expect sustained results, reinforcing the need to align treatment strategies with these expectations. They also highlighted practical tools, such as routine assessment of body surface area (BSA) and Investigator’s Global Assessment (IGA), are efficient ways to monitor progress and prompt treatment reassessment when targets are not met. These measures can also streamline clinical workflows and support performance metrics. The panelists conclude by encouraging clinicians to become familiar with a core set of biologic therapies and to confidently communicate their benefits to patients with psoriasis.

Thank you for watching this peer exchange series on on-treatment remission in psoriasis. Please subscribe to our newsletter for information on upcoming video series.

Videos

Experts explain managing psoriasis biologic failures: reassess response, use topicals, and switch smarter to reach near‑clear skin.

Managing Treatment Failure in Psoriasis

In this episode, ‘Managing Treatment Failure in Psoriasis,’ the expert dermatologists focus on the practical management of treatment failure in psoriasis. The faculty discussed how to differentiate between primary non-response and secondary loss of response, emphasizing that these scenarios require distinct clinical approaches. Rather than immediately discontinuing therapy, clinicians are encouraged to assess disease patterns, patient satisfaction, and treatment adherence in patients with psoriasis.

They discuss the value of maintaining open communication with patients, particularly when evaluating treatment success. Even when clinical improvement is observed, patient perception of disease control remains critical in guiding next steps. The panelists highlight that some patients may be satisfied with partial improvement, while others may seek more complete clearance, reinforcing the need for shared decision-making.

The panelists explore strategies for managing suboptimal response include optimizing current therapy with adjunctive treatments, switching within the same biologic class, or transitioning to a different mechanism of action. They also introduce the concept of multi-biologic failure, where patients experience diminishing responses across multiple therapies. They raise the question of whether initiating treatment with the most effective therapy upfront may improve long-term outcomes and reduce the risk of treatment resistance. The faculty emphasize a proactive and flexible approach to treatment optimization, with the goal of achieving sustained disease control.

The next episode in this series, ‘Implementing Remission Goals in Psoriasis Practice,’ features the panelists highlighting practical approaches to implementing remission-focused care in psoriasis, emphasizing that achieving and maintaining clear skin is an attainable goal. It reinforces the importance of setting expectations, using simple assessment tools, and confidently selecting effective therapies to optimize patient outcomes.

Safety Considerations for IL-17 Inhibitors in Psoriasis 

This episode, titled ‘Safety Considerations for IL-17 Inhibitors in Psoriasis,’ the expert faculty focuses on the safety profile of IL-17 inhibitors in psoriasis, highlighting both class-wide considerations and differences among individual therapies. The panelists emphasize that modern biologics targeting the IL-17 pathway are generally well tolerated, with favorable safety profiles compared with earlier generations of systemic therapies.

The expert dermatologists discuss how there is an increased risk of mild fungal infections, such as tinea and candidiasis, which is a known class effect related to IL-17 inhibitors. They note that these infections are typically manageable, and often occur early in treatment without recurring in most patients. This safety signal reflects the targeted nature of IL-17 inhibition rather than broad immunosuppression.

The panelists also address the potential association between IL-17 inhibitors and inflammatory bowel disease (IBD), including both exacerbation of preexisting disease and possible new onset. The faculty highlights the importance of screening for personal and family history of IBD and incorporating this information into treatment selection and patient counseling. Emerging insights into mechanistic differences within the IL-17 pathway suggest that variations in cytokine targeting may influence these risks, although this remains an area of ongoing research. The expert faculty reinforces the importance of balancing efficacy with safety while tailoring treatment decisions to individual patient profiles in psoriasis care.

In the next episode, ‘Managing Treatment Failure in Psoriasis,’ panelists examine strategies for managing treatment failure in psoriasis, including differentiating primary and secondary non-response and optimizing therapy. It highlights the importance of patient-centered decision-making and the potential value of initiating treatments early to improve long-term outcomes.

IL-17 inhibitors clear psoriasis fast; meta-analyses highlight brodalumab, bimekizumab and ixekizumab, with flexible dosing that builds patient confidence.

Safety Considerations for IL-17 Inhibitors in Psoriasis

Rapid Response in Psoriasis Treatment

In ‘Rapid Response in Psoriasis Treatment,’ our panel explores the clinical importance of rapid treatment response in psoriasis and how speed of efficacy has become valued in biologic therapy selection. While early treatment paradigms prioritized long-term outcomes over initial response, the faculty discuss how rapid skin clearance is now recognized as both clinically meaningful and impactful for patients. Certain life events, such as social engagements, relationships, or seasonal activities, can heighten the urgency for faster improvement, making speed of response an important consideration in real-world practice.

The panelists highlight that IL-17 inhibitors as a class are generally associated with rapid onset of action, with some agents demonstrating faster response rates than others based on clinical trial and meta-analysis data. However, the discussion emphasizes that differences in onset, while measurable, may not always be clinically significant across all patients. Instead, rapid improvement can serve as an important factor in building patient confidence and strengthening the physician–patient relationship, particularly early in treatment.

They also address practical considerations related to dosing strategies, including induction regimens and injection frequency. While some therapies require more frequent dosing upfront to achieve rapid control, others offer simplified regimens without compromising efficacy. The faculty note that clinicians no longer need to trade off speed for long-term outcomes, as newer therapies can deliver both rapid and sustained disease control. This discussion reinforces the growing role of treatment speed as part of a comprehensive, patient-centered approach to psoriasis management.

Our next episode, ‘Safety Considerations for IL-17 Inhibitors in Psoriasis,’ the expert faculty reviews the safety profile of IL-17 inhibitors in psoriasis, including common class effects such as mild fungal infections and considerations related to inflammatory bowel disease. It emphasizes the importance of individualized risk assessment and patient counseling when selecting targeted therapies.

Clinicians unpack dual IL‑17A/F blockade in psoriasis and reveal why long‑term efficacy claims vary without rigorous head‑to‑head data.

Linda Stein Gold, MD

Articles